Development of efficacious combination therapies with RNA Polymerase I inhibitors

This study aims to develop effective combination therapies using RNA Polymerase I (Pol I) inhibitors to enhance therapeutic efficacy and combat resistance in cancer treatment through synergistic effects with other drugs or treatments.

school Student intake
This project is open for Honours, Masters and PhD students.
label Research theme

Research themes

traffic Project status

Project status

Potential
Contact
contact_support Contact
Contact name
Dr Rita Ferreira
Contact position
Supervisor
Contact email

Content navigation

About

This study focuses on developing effective combination therapies involving RNA Polymerase I (Pol I) inhibitors. By exploring synergistic effects with other drugs or treatments, the research aims to enhance therapeutic efficacy and potentially overcome resistance in cancer treatment.

Members

Supervisor

Rita Ferreira

Senior Fellow

Amee George

Lead, ANU Centre for Therapeutic Discovery (ACTD)
Platform Manager, National Therapeutic mRNA Platform
Associate Professor in Pharmacogenomic Technologies
Group Leader

Ross Hannan

Group Leader
Deputy Dean, Research, CHM
NHMRC Principle Res. Fellow